Health Cytokinetics to Announce First Quarter Results on May 4, 2023 James Pereira Apr 21, 2023 <!-- Name:DistributionId Value:8812472 --> <!--… Read More...
Health Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society… James Pereira Jun 4, 2022 SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today… Read More...
Health Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) James Pereira Jun 2, 2022 SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today… Read More...
Health Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at… James Pereira Apr 3, 2022 No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in… Read More...
Health Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of… James Pereira Apr 2, 2022 SOUTH SAN FRANCISCO, Calif., April 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today… Read More...
Health Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the… James Pereira Feb 5, 2022 PDUFA Target Action Date Set for November 30, 2022 FDA is Currently Not Planning to Hold an Advisory Committee Meeting… Read More...
Health Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical… James Pereira Sep 12, 2021 Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with… Read More...
Health Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart… James Pereira May 16, 2021 SOUTH SAN FRANCISCO, Calif., May 16, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today… Read More...